NEW YORK , April 19, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc. ("Checkmate" or the "Company") , in connection with the proposed acquisition of the Company by Regeneron Pharmaceuticals, Inc. /zigman2/quotes/203149337/composite REGN +0.72% , via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $10.50 in cash for each share of Checkmate common stock owned. The transaction is valued at $250 million.
If you own Checkmate shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
305 Broadway, 7 [th] Floor
New York, NY 10007
(212) 682-3025 (888) email@example.com
Weiss Law is investigating whether (i) Checkmate's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $10.50 per-share merger consideration adequately compensates Checkmate's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at firstname.lastname@example.org
SOURCE Weiss Law
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.
Copyright (C) 2022 PR Newswire. All rights reserved